Cup and Handle formation
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions...
This is a great example of a chart that makes me realize there is much more to learn. I know there is a way to classify almost every market, but for the life of me I don't know this one.
That makes me all the more motivated to monitor it, however.
The stock is showing a good wave structure
It has a bit of spiky pullback during its wave 4
The candles have broken the highs and failed a few times
Apart from the above, it's looking really good for another push-up
I've lost 0.5R on it once. If this second and final attempt goes well
then I will recover the previous investment and plus 1R on top.
So here we...
NASDAQ:OCUL is about to break out. Long the break out at 20, the anticipated price action is shown on the chart, stop at 17$.
Hit the like button and follow if you find this useful :)
This is only my own view and not financial advice, do your own analysis before buying or selling
Happy Trading!
Here we have another stock with a lovely wave 3 up
a nice not too complex wave 4 down
price has squeezed into a tight box allowing us to take a tight 3 dollar stop
Entry Price $21
Stop $18 (or maybe even 18.50)
Target 1: $23.50
Target 2: $26
Fingers Crossed!!!
Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the...
$OCUL
someone bought a bunch of Jan 2021 expiry 23C's early this afternoon. This name isn't a big option trader with average daily option volume barely over 400 contracts.
Volume today on the 23C strike is currently 1058 against only 16 contract OI. They paid around 1.60 to 1.80.
Contextual immersion trading strategy idea.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology.
The share price rose after the company announced topline phase 1 clinical trial results of...
If we close above cloud today, this ticker will hit all 4 entry conditions. OCUL historically has a 64.7% win rate and 1.62% average gain using this strategy.
OCUL
OCUL has a pattern of descending triangles over the past 4-months (July-November 2019). The company launched its second commercial product Dextenza in the 2nd quarter where it gave away free samples. Its other product 'ReSure Sealent' has posted weak sales numbers ($472K in 1Q19 and ~600K in 2Q19). Dextenza is priced at $850 and is essentially an...
OCUL has had many difficulties over the past number of years, but finally, after shaking up management, getting over manufacturing and regulatory hurdles, and now receiving a broadened label and clarity on reimbursement the stock looks like a screaming buy. While it is always tricky to invest when a biopharma company is going through a product launch, it would...
Bearish head and shoulders setup. Most likely no sales. I will look to add after retracement. Potential AB=BC harmonic correction.
Disclosure: I do not own shares of OCUL. This is not a note to buy or sell. please do your hw before investing.
